The high prevalence of PCOS in our population and its associated clinical morbidities including obesity, metabolic dysfunction, neoplastic risk, subfertility, and menstrual abnormalities suggest that this disorder can be a significant economic burden. Azziz et al sought to determine the economic burden of PCOS during the reproductive life span by performing a systematic review of the literature to obtain epidemiologic data on PCOS and its clinical consequences and costs, then using the general societal costs of different health consequences. Overall they found that the total cost of evaluating and providing care to PCOS women in the United States in the reproductive age group was $4.36 billion in 2007, without considering any of the potential obstetrical complications. The cost of T2DM mellitus was approximately 40% of the entire economic burden attributable to PCOS. Additionally, the study noted that the initial diagnostic cost of evaluating someone with PCOS was minimal compared with the overall economic cost and that a more liberal screening policy for women with signs or symptoms of PCOS is a cost-effective approach to the disorder, as early diagnosis and treatment has a high probability of ameliorating or preventing the more serious consequences of the disorder.
Semin Reprod Med. 2017;35(3):271-281. © 2017 Thieme Medical Publishers